Dr. Bascope brings an extensive background in pharmaceutical research, natural compound synthesis, and regulatory compliance. As a recognized leader in biotechnology, API manufacturing, and pharmaceutical formulation, he has pioneered advancements in molecular synthesis and played a key role in developing innovative approaches to controlled substance research and global compliance structures.
As an advisor to KRTL Biotech and now a formal leader within KRTL Holding Group, Dr. Bascope will drive scientific strategy, regulatory alignment, and international research partnerships to solidify KRTL's position at the forefront of global biotechnology advancements. His leadership will play a crucial role in integrating cutting-edge research into commercial applications, optimizing pharmaceutical supply chains, and ensuring compliance with FDA, DEA, and global regulatory bodies.
"Dr. Marcelo Bascopé's expertise is unparalleled, and his addition to our leadership team represents a monumental step in KRTL's expansion as a global biopharmaceutical leader," said Cesar Herrera, CEO of KRTL Holding Group Inc. "His vast knowledge of pharmaceutical sciences, international regulatory frameworks, and innovative research methodologies will be instrumental as we scale our operations and enter new markets."
Dr. Bascopé's appointment comes at a pivotal time for KRTL, as the company accelerates joint ventures in Bolivia and explores next-generation pharmaceutical formulations. His deep understanding of botanical APIs, controlled substance analytics, and international compliance aligns seamlessly with KRTL's mission to advance science-driven healthcare solutions.
About KRTL Holding Group Inc.
KRTL Holding Group Inc. is a dynamic holding company operating through its wholly owned subsidiaries, KRTL Biotech, Inc. and KRTL International Corp. These subsidiaries specialize in biopharmaceutical innovation, international trade, and compliance-driven healthcare advancements. By leveraging strategic mergers, acquisitions, and joint ventures, KRTL Holding Group continues to push the boundaries of scientific research, regulatory compliance, and global business solutions.
Additional information on KRTL is available online at www.krtlholding.com and www.krtl-icc.com and www.krtlbiotech.com.
This press release contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. These statements include, but are not limited to, anticipated business developments, regulatory advancements, and strategic growth plans. Such forward-looking statements involve known and unknown risks that may cause actual results to differ materially from those expressed or implied.
KRTL Holding Group assumes no obligation to update or revise forward-looking statements, except as required by law. Any updates will be made in accordance with applicable SEC regulations and disclosure obligations. Readers are cautioned not to place undue reliance on forward-looking statements.
コメント